Should I buy or sell Black Diamond Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Black Diamond Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BDTX shares. View BDTX analyst ratings or view top-rated stocks .

What is Black Diamond Therapeutics' stock price target for 2024?

4 equities research analysts have issued 1-year target prices for Black Diamond Therapeutics' stock. Their BDTX share price targets range from $10.00 to $16.00. On average, they expect the company's share price to reach $12.25 in the next twelve months. This suggests a possible upside of 132.4% from the stock's current price. View analysts price targets for BDTX or view top-rated stocks among Wall Street analysts .

How have BDTX shares performed in 2024?

Black Diamond Therapeutics' stock was trading at $2.81 at the beginning of 2024. Since then, BDTX shares have increased by 87.5% and is now trading at $5.27. View the best growth stocks for 2024 here .

Are investors shorting Black Diamond Therapeutics?

Black Diamond Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,040,000 shares, an increase of 12.7% from the March 15th total of 1,810,000 shares. Based on an average trading volume of 592,500 shares, the days-to-cover ratio is currently 3.4 days. View Black Diamond Therapeutics' Short Interest .

When is Black Diamond Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our BDTX earnings forecast .

How were Black Diamond Therapeutics' earnings last quarter?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) issued its earnings results on Tuesday, March, 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.13.

What other stocks do shareholders of Black Diamond Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Black Diamond Therapeutics investors own include Alector (ALEC) , Alteryx (AYX) , Editas Medicine (EDIT) , Gossamer Bio (GOSS) , Micron Technology (MU) , NVIDIA (NVDA) , Homology Medicines (FIXX) , II-VI (IIVI) , Intel (INTC) and Invitae (NVTA) .

When did Black Diamond Therapeutics IPO?

Black Diamond Therapeutics (BDTX) raised $151 million in an IPO on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of Black Diamond Therapeutics?

Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BDTX

Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis

→ Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad)

Free BDTX Stock Alerts

$5.27

-0.43 (-7.54%)

(As of 02:09 PM ET)

Compare

Today's Range: $5.13
▼
$5.72
50-Day Range: $3.78
▼
$5.74
52-Week Range: $1.43
▼
$6.85

Volume: 1.56 million shs
Average Volume: 586,846 shs
Market Capitalization: $272.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.25

Get Black Diamond Therapeutics alerts:

Black Diamond Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 132.4% Upside
$12.25 Price Target
Short Interest: Healthy
3.94% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.36
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.71) to ($1.79) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.41 out of 5 stars

Medical Sector

489th out of 914 stocks

Biological Products, Except Diagnostic Industry

82nd out of 151 stocks

3.5

Analyst's Opinion

Consensus Rating
Black Diamond Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Black Diamond Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.94% of the outstanding shares of Black Diamond Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Black Diamond Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Black Diamond Therapeutics has recently increased by 12.71%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Black Diamond Therapeutics does not currently pay a dividend.
Dividend Growth
Black Diamond Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BDTX.

4.1

News and Social Media Coverage

News Sentiment
Black Diamond Therapeutics has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Black Diamond Therapeutics this week, compared to 1 article on an average week.
Search Interest
8 people have searched for BDTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
7 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.07% of the stock of Black Diamond Therapeutics is held by insiders.
Percentage Held by Institutions
95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Black Diamond Therapeutics are expected to decrease in the coming year, from ($1.71) to ($1.79) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Black Diamond Therapeutics is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Black Diamond Therapeutics is -2.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Black Diamond Therapeutics has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad GoldenCrest Metals

Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars

Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.

Learn More Now

About Black Diamond Therapeutics Stock (NASDAQ:BDTX)

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

BDTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BDTX Stock News Headlines

April 17, 2024 | americanbankingnews.com

Cognition Therapeutics (NASDAQ:CGTX) and Black Diamond Therapeutics (NASDAQ:BDTX) Head to Head Review

April 12, 2024 | americanbankingnews.com

Black Diamond Therapeutics, Inc. Expected to Earn Q1 2024 Earnings of ($0.41) Per Share (NASDAQ:BDTX)

April 18, 2024 | The Freeport Society (Ad)

Next President (Not Trump. Not Biden.)

Do you want to see who I believe will be the next president of the U.S.A? It won't be Biden… And it won't be Trump.

April 11, 2024 | globenewswire.com

Black Diamond Therapeutics Announces Changes to Board of Directors

April 9, 2024 | americanbankingnews.com

Wedbush Increases Black Diamond Therapeutics (NASDAQ:BDTX) Price Target to $16.00

April 8, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know

April 7, 2024 | globenewswire.com

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

April 3, 2024 | globenewswire.com

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

April 18, 2024 | The Freeport Society (Ad)

Next President (Not Trump. Not Biden.)

Do you want to see who I believe will be the next president of the U.S.A? It won't be Biden… And it won't be Trump.

March 14, 2024 | finance.yahoo.com

Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ...

March 12, 2024 | globenewswire.com

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 5, 2024 | globenewswire.com

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

February 29, 2024 | seekingalpha.com

BDTX Black Diamond Therapeutics, Inc.

February 28, 2024 | globenewswire.com

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

February 16, 2024 | uk.investing.com

Black Diamond Therapeutics Inc (BDTX)

January 24, 2024 | wsj.com

Black Diamond Therapeutics Inc.

January 4, 2024 | finance.yahoo.com

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

December 14, 2023 | msn.com

Black Diamond reports positive topline data for GBM drug

December 14, 2023 | markets.businessinsider.com

Buy Rating Reaffirmed for Black Diamond Therapeutics Amid Promising BDTX-1535 Trial Results and Strategic Development

December 13, 2023 | finance.yahoo.com

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

December 5, 2023 | finance.yahoo.com

With 58% ownership, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) boasts of strong institutional backing

November 9, 2023 | washingtonpost.com

Solitario: Q3 Earnings Snapshot

November 6, 2023 | finance.yahoo.com

Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update

November 6, 2023 | finance.yahoo.com

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 31, 2023 | morningstar.com

Black Diamond Therapeutics Inc Ordinary Shares BDTX

October 17, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Black Diamond Therapeutics (BDTX), Ultragenyx Pharmaceutical (RARE)

October 16, 2023 | markets.businessinsider.com

Black Diamond Therapeutics (BDTX) Receives a Buy from Piper Sandler

See More Headlines

Receive BDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:BDTX
CUSIP: N/A
CIK: 1701541
Web: N/A
Phone: 617-252-0848
Fax: N/A
Employees: 54
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.25
High Stock Price Target: $16.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +114.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.88)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-82,440,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -76.43%
Return on Assets: -56.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.82
Quick Ratio: 6.82

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.26 per share
Price / Book: 2.52

Miscellaneous

Outstanding Shares: 51,720,000
Free Float: 47,027,000
Market Cap: $294.80 million
Optionable: Optionable
Beta: 2.64

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Mark A. Velleca M.D. (Age 60)
Ph.D., CEO, President & Chairman
Comp: $43.89k
Dr. David M. Epstein Ph.D. (Age 65)
Co-Founder & Director
Comp: $885.08k
Dr. Fang Ni Pharm.D. (Age 37)
CFO, Principal Financial Officer and Chief Business Officer
Comp: $656.33k
Mr. Brent Hatzis-Schoch Esq. (Age 59)
J.D., COO & General Counsel
Comp: $683.29k
Dr. Elizabeth Buck Ph.D. (Age 49)
Co-Founder & Chief Scientific Officer
Comp: $340.47k
Ms. Erika Jones (Age 39)
VP of Finance, Corporate Controller & Principal Accounting Officer
Ms. Elizabeth L. Montgomery (Age 52)
Chief People Officer
Dr. Sergey Yurasov M.D. (Age 55)
Ph.D., Chief Medical Officer
Ms. Melanie Morrison
Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BDTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Black Diamond Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Black Diamond Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BDTX shares.
View BDTX analyst ratings or view top-rated stocks.
What is Black Diamond Therapeutics' stock price target for 2024?: 4 equities research analysts have issued 1-year target prices for Black Diamond Therapeutics' stock. Their BDTX share price targets range from $10.00 to $16.00. On average, they expect the company's share price to reach $12.25 in the next twelve months. This suggests a possible upside of 132.4% from the stock's current price.
View analysts price targets for BDTX or view top-rated stocks among Wall Street analysts.
How have BDTX shares performed in 2024?: Black Diamond Therapeutics' stock was trading at $2.81 at the beginning of 2024. Since then, BDTX shares have increased by 87.5% and is now trading at $5.27.
View the best growth stocks for 2024 here.
Are investors shorting Black Diamond Therapeutics?: Black Diamond Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,040,000 shares, an increase of 12.7% from the March 15th total of 1,810,000 shares. Based on an average trading volume of 592,500 shares, the days-to-cover ratio is currently 3.4 days.
View Black Diamond Therapeutics' Short Interest.
When is Black Diamond Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BDTX earnings forecast.

How were Black Diamond Therapeutics' earnings last quarter?: Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) issued its earnings results on Tuesday, March, 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.13.
What other stocks do shareholders of Black Diamond Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Black Diamond Therapeutics investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA), Homology Medicines (FIXX), II-VI (IIVI), Intel (INTC) and Invitae (NVTA).
When did Black Diamond Therapeutics IPO?: Black Diamond Therapeutics (BDTX) raised $151 million in an IPO on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager.
How do I buy shares of Black Diamond Therapeutics?: Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BDTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial